Package Size Information

INSULIN (h), [¹²⁵i]-Product Number: NEX420

Insulin, Human Recombinant

LOT SPECIFIC INFORMATION

			r ackage oize information		
CALCULATED AS OF:	;	8-Apr-2024	Package Size		
			as of		
LOT NUMBER:	LC51740		17-May-2024		
			370 kBq		
SPECIFIC ACTIVIT	81.4	TBq/mmol	10 μCi		
	2200	Ci/mmol	1.85 MBq		
	14	MBq/µg	50 μCi		
	378.8	µCi/µg			

RADIOCHEMICAL PURITY: ≥ 95%

MOLECULAR WEIGHT: 5931.6

PACKAGING: [¹²⁵I]-Insulin (h) is lyophilized from 0.05M sodium phosphate buffer, pH 7.4, containing 0.2M sodium chloride, 1M glycine, 0.25% bovine serum albumin, and 500KIU/ML Aprotinin. It is shipped on dry ice.

STABILITY AND STORAGE: The lyophilized [¹²⁵]-Insulin (h) should be stored at 4°C or lower. Following reconstitution with distilled water to a concentration of approximately 50 μ Ci/ml on calibration date, aliquot and store at -20°C or lower. Under these conditions the product is stable and usable for at least six weeks after fresh lot date.

SPECIFIC ACTIVITY: The initial specific activity of [¹²⁵I]-Insulin (h) is expected to be 2200 Ci/mmol (81 TBq/mmol), 378.8 µCi/µg (14.0 MBq/µg). Preparative HPLC is used to separate unlabeled Insulin from [¹²⁵I]-Insulin (h). Upon decay [¹²⁵I]-Insulin (h) undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on ¹²⁵I decay and decay catastrophe of ¹²⁵I labeled compounds are available.¹⁻⁵

RADIOCHEMICAL PURITY: Initially greater than 95% radiochemically pure as determined by HPLC

PREPARATIVE PROCEDURE: [¹²⁵I]-Insulin (h) is radioiodinated with no carrier added ¹²⁵I using the LPO iodination procedure and is purified by reversed phase HPLC.

AVAILABILITY: [¹²⁵I]-Insulin (h) is routinely available from stock and is prepared fresh and packaged for shipment on the second Monday of each month. Please inquire for larger package sizes.

APPLICATIONS: [¹²⁵]-Insulin (h) is suitable for the use in radioimmunoassay as well as receptor binding assay.

HAZARD WARNING: This product contains a component which is harmful by contact, ingestion or inhalation. It is irritating to the eyes, skin and respiratory tract.

RADIATION UNSHIELDED: 280mR/hr/mCi at vial surface .

REFERENCES:

- 1. Doyle, V.M., Buhler, F.R., Burgisser, E., Eur. J. Pharm. 99 353 (1984).
- 2. Schmidt, J., J. Biol. Chem. 259 1660 (1984).
- 3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., J. Biol. Chem. 257 1418 (1982).
- 4. Berridge, M.S., Jiang, V.W., Welch, M.J., *Rad. Res. 82 467 (1980).*
- 5. Charlton, D.E., Rad. Res. 107 163 (1986).

IODINE-125 DECAY CHART HALF LIFE=60 days

Radiations Gamma 35.5 keV (7%), X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
	0 1	0.977	0.955	0.933	0.912	0.891	0.871	0.851	0.831	0.812
2	0 0.794	0.776	0.758	0.741	0.724	0.707	0.691	0.675	0.66	0.645
4	0 0.63	0.616	0.602	0.588	0.574	0.561	0.548	0.536	0.524	0.512
6	0 0.5	0.489	0.477	0.467	0.456	0.445	0.435	0.425	0.416	0.406
8	0 0.397	0.388	0.379	0.37	0.362	0.354	0.345	0.338	0.33	0.322
10	0 0.315	0.308	0.301	0.294	0.287	0.281	0.274	0.268	0.262	0.256
12	0 0.25	0.244	0.239	0.233	0.228	0.223	0.218	0.213	0.208	0.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



Revvity, Inc. 940 Winter Street Waltham, MA 024<u>51 USA</u>

(800) 762-4000 www.revvity.com For a complete listing of our global offices, visit <u>www.revvity.com</u> Copyright ©2023, Revvity, Inc. All rights reserved.